TOP > 外国特許検索 > HAIR GROWTH PROMOTER

HAIR GROWTH PROMOTER

外国特許コード F100002329
掲載日 2010年12月14日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2008JP069004
国際公開番号 WO 2009054361
国際出願日 平成20年10月21日(2008.10.21)
国際公開日 平成21年4月30日(2009.4.30)
優先権データ
  • 特願2007-273889 (2007.10.22) JP
発明の名称 (英語) HAIR GROWTH PROMOTER
発明の概要(英語) Disclosed is a hair growth promoter which can induce more efficient hair growth when applied externally, and which has little adverse side effects. Specifically disclosed is a hair growth promoter which comprises, as an active ingredient, a peptide compound containing 9 to 13 arginine residues and the amino acid sequence depicted in SEQ ID NO:1, wherein the peptide compound is a CaN/NFAT pathway-specific inhibitor having a cell membrane permeability.
従来技術、競合技術の概要(英語) BACKGROUND ART
Hair growth effect is often found sing the current product, American Food and Drug Administration (FDA) male admitted effective drug is minoxidil and finasteride only one 2. A vasodilating effect and a minoxidil Messenger AG et al. with respect to the hair on the basis of the phenomenon described (British Journal of Dermatology, year 2004, the first winding 150, see p.186-194). With respect to the finasteride, reporting for the first time (Journal of Clinical Endocrinology and Metabolism Diani AR et al., year 1992, the first winding 74, see p.345-350), to inhibit the growth of the hair from the testosterone is converted to dihydrotestosterone by inhibiting the enzyme, and the growth of the hair.
However, these conventional 2 both the two agents is a low-molecular compound, has a critical problem in distributed respectively. Is first minoxidil, originally developed as a vasodilator as MIMIC, increasing the circulation amount of blood around the hair roots to the idea that responsible for the induction of hair growth generally. However the hair roots of the hair growth promoting and increased blood flow related directly to evidence is poor, such that the elucidation of the details of the mechanism of hair still has not been made. For the side effects, the fatal arrhythmias in particular change in the hemodynamics of the suggested the presence of a.
Finasteride is then, particularly with respect to the male pattern is currently most valid but recognized as oral treatments, reminders Welfare its mechanism of action according to sex (male only) cannot be used, the drug to the fetus sex teratogenicity has strict with respect to the recommended contact inhibition. In addition, as a side effect seen to decline 1-5% libido, gynecomastia is unknown frequency have arisen.
Hair in the hair growth mechanism is engaged in the study as well as, people that is widely and generally non-exhaustive list of interest in the topic is constantly. Hair growth mechanism heretofore has been studied and a wide range, various related factors have been identified, one of which 1 calcineurin, NFAT (hereinafter, simply referred to as path CaN/NFAT) path is.
Nuclear factor of activated T cells NFAT which is an acronym for, as shown in this name, important immune-response related originally discovered as a transcription factor. However subsequent studies CaN/NFAT path as well as the immune system, cardiac nerve, pancreas plays an important role in many organs was found. Hair growth mechanism for the relevance of the pathway, Gafter-Gvili et al., the immunosuppressive agent cyclosporin A (hereinafter, simply referred to as CsA) as a side effect of all hair- be deeper to originate with a famous hirsutism, hair follicles in the keratinocytes in the phosphatase calcineurin (hereinafter, simply referred to as CaN) might be inhibited by the enzymatic activity of CsA in, further NFAT dephosphorylation and nuclear import relating to the transcriptional control of the cell cycle is followed by a controlled, induced hair growth as a result has been reported (for example, American Journal of Physiology, 2003 year, the first winding 284, see p.1593-1603). And the association of hair CaN/NFAT path, then in work by other groups also verified, by many researchers and widely accepted.
On the other hand, the enzymatic activity of CsA is itself in order to suppress CaN, well as path CaN CaN/NFAT involving many reaction is impeded and there is a possibility that, the side effects caused by systemic administration of CsA renal disorders and diarrhea is suspected in the surface layer. In addition, is CsA, in topical application in the skin induced hair growth has been reported that, oral ingestion in the same manner as the expected number of side effects. The inventors of the present invention, the enzymatic activity of the previously CaN without inhibiting NFAT nuclear translocation of the peptide to inhibit specifically developed drug, immunosuppressive effect and also demonstrated that the suppression effect for cardiac hypertrophy (see Japanese Patent Application JP-2003-252898).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • National University Corporation Okayama University
  • 発明者(英語)
  • MATSUI, Hideki
  • TOMIZAWA, Kazuhito
  • FUJIMURA, Atsushi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MT NL NO PL PT RO SE SI SK TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

PAGE TOP

close
close
close
close
close
close